Sofwave Medical
Israeli medical-aesthetics company developing non-invasive ultrasound systems for skin tightening, wrinkle reduction, and cellulite appearance improvement.
Last updated August 31, 2026
AI crawler reads
No AI crawler has read this profile since Oct 28, 2026.
Overview
Sofwave Medical is an Israeli medical-aesthetics company whose business centers on non-invasive ultrasound technology for dermatological and aesthetic treatments. The company was established in 2015 in Yokneam, Israel, through the Alon Medtech Ventures incubator, which is associated with the Israel Innovation Authority. It was founded by Shimon Eckhouse, a prominent entrepreneur in the Israeli medical-aesthetics sector, and Ariel Sverdlik, who serves as the company's chief technology officer. Eckhouse is also identified as the company's chairman. The company developed its commercial platform around Synchronous Ultrasound Parallel Beam technology. The system uses multiple cooled transducers to deliver ultrasound energy into the dermis while limiting injury to the epidermis. The intended treatment area is approximately 1.5 millimetres below the skin surface. Sofwave positions the treatment as a non-surgical approach to improving facial and neck skin laxity and the appearance of facial lines and wrinkles. The platform has also been used for short-term improvement in the appearance of cellulite. Treatment is described as taking roughly 30 to 45 minutes, with limited downtime and the possibility of visible improvement after a single treatment, although clinical outcomes can vary by patient and indication. Sofwave's United States commercial presence was formalized in September 2019 through the incorporation of Sofwave Medical Inc., a Delaware subsidiary that functions as the group's US marketing branch. The company began selling its product commercially in late 2019 after raising funding led by XT Hi-Tech, associated with the Ofer family. In May 2021, Sofwave completed an initial public offering on the Tel Aviv Stock Exchange, raising $50 million at a reported pre-money valuation of $192 million. The listing gave the company access to public capital while it expanded distribution and clinical adoption in North America and other markets. The company has reported regulatory clearances or approvals for its system in several jurisdictions, including the United States, the European market, Israel, and Australia. The reference material identifies FDA, CE, AMAR, MOHW, and TGA clearances or approvals, although the precise indication and regulatory status can differ by market and should be checked against current regulator records. Sofwave has marketed the platform primarily to medical professionals and aesthetic clinics rather than directly to consumers. Sofwave's commercial positioning is that of a premium or upper-mid-market provider of energy-based medical-aesthetic equipment. Its principal competitive distinction is the use of parallel ultrasound beams and cooled transducers to create controlled thermal zones in the dermis without intentionally ablating the skin surface. The company competes in a broader market that includes other non-invasive skin-tightening technologies; the reference material specifically identifies Ulthera as a direct competitor. Sofwave has also received recognition from beauty and consumer publications, including Elle in 2021 and NewBeauty, Shape, and Cosmopolitan in 2022. Its continuing business depends on regulatory maintenance, practitioner adoption, international distribution, clinical evidence, and the ability to differentiate its system from competing ultrasound, radio-frequency, laser, and energy-based treatments.
History
Sofwave Medical was founded in 2015 by Shimon Eckhouse and Ariel Sverdlik in the Alon Medtech Ventures incubator in Yokneam, Israel. The company's creation drew on Eckhouse's experience in medical aesthetics and on Sverdlik's technical background. Eckhouse had previously founded or backed a number of companies in the field, including Lumenis and Syneron Medical, while Sverdlik became responsible for technology development at Sofwave. The company developed a proprietary platform based on Synchronous Ultrasound Parallel Beam technology. The system is designed to deliver controlled ultrasound energy through seven cooled transducers. Its operating concept is to produce thermal zones in the dermis at approximately 1.5 millimetres beneath the skin surface while avoiding intentional damage to the epidermis. Sofwave presents this approach as a non-invasive alternative for improving facial lines, wrinkles, and skin laxity, with an additional use for short-term improvement in the appearance of cellulite. Sofwave's US corporate and commercial infrastructure expanded in September 2019 with the incorporation of Sofwave Medical Inc. in Delaware. The subsidiary became the group's US marketing branch. That year the company raised $8.4 million in financing led by XT Hi-Tech, associated with the Ofer family, and began commercial sales late in 2019. In May 2021, Sofwave became a publicly traded company through an initial public offering on the Tel Aviv Stock Exchange. The offering reportedly raised $50 million at a pre-money valuation of $192 million. The company subsequently reported rapid early commercial growth. Its reported 2021 revenue was $21.8 million, compared with $4.3 million in 2020 based on the cited 408 percent increase. Gross income rose from $2.6 million to $16.2 million over the same period, while the operating loss widened from $6.6 million to $8.9 million. North American revenue increased from $3.4 million in 2020 to $13.5 million in 2021. The company's device has been cleared or approved in multiple jurisdictions, with the reference material naming FDA, CE, AMAR, MOHW, and TGA pathways. These designations should not be assumed to represent identical indications in every country. Sofwave has focused on distribution through aesthetic physicians, dermatologists, and clinics, where treatments are performed using its professional equipment. Brand visibility was supported by editorial and consumer awards, including an Elle award in 2021 and awards associated with NewBeauty, Shape, and Cosmopolitan in 2022. Sofwave operates in a competitive energy-based aesthetics market. Ulthera is identified as a direct competitor, while the broader category also includes other ultrasound, radio-frequency, laser, and light-based systems. The company's ongoing strategic priorities are therefore tied to maintaining regulatory access, developing clinical support, expanding international sales, and establishing a differentiated practitioner proposition for non-invasive skin tightening.
- 2022
Consumer beauty recognitions
[1]The brand received recognitions associated with NewBeauty, Shape, and Cosmopolitan.
- 2021
Tel Aviv Stock Exchange IPO
[1]Sofwave raised $50 million in an initial public offering on the Tel Aviv Stock Exchange.
- 2021
Elle recognition
[1]The Sofwave brand received an award cited by the reference material as an Elle award.
- 2019
US subsidiary incorporated
[1]Sofwave Medical Inc. was incorporated in Delaware as the group's US marketing subsidiary.
- 2019
Financing and commercial launch
[1]The company raised $8.4 million in financing and began selling its product late in the year.
- 2015
Company established in Israel
[1]Sofwave was founded by Shimon Eckhouse and Ariel Sverdlik through the Alon Medtech Ventures incubator in Yokneam, Israel.
Products and positioning
Premium medical-aesthetics equipment provider focused on non-invasive ultrasound skin tightening and wrinkle treatment.
Non-invasive medical-aesthetic ultrasound system · 2019
Sofwave system
Sofwave's flagship professional device uses Synchronous Ultrasound Parallel Beam technology and seven cooled transducers to deliver ultrasound energy to the dermis. The system is intended to create controlled thermal zones without injuring the epidermis. Its aesthetic applications include improvement in facial and neck skin laxity and facial lines and wrinkles, as well as short-term improvement in the appearance of cellulite. The reference material describes typical treatment sessions as lasting approximately 30 to 45 minutes with minimal downtime.
Brand decisions
2021
Initial public offering on the Tel Aviv Stock ExchangeM&ABackground
The company required capital to support commercialization and international expansion of its ultrasound aesthetic platform.
Action taken
Sofwave completed an IPO on the Tel Aviv Stock Exchange and raised $50 million at a reported pre-money valuation of $192 million.
Aftermath
The transaction made Sofwave a publicly traded company and provided additional funding for growth.
IPO proceeds. $50 million raised (May 2021)
2019
Establishment of a dedicated US marketing subsidiaryStrategyBackground
Sofwave sought to build a direct commercial presence in the United States, one of the most important markets for aesthetic medicine.
Action taken
The group incorporated Sofwave Medical Inc. in Delaware as a wholly owned US marketing branch.
Aftermath
The subsidiary supported US commercialization as the company began selling its product commercially in late 2019.
Recent events
- 2022
Sofwave receives beauty-publication awards[1]
Other
The brand received recognition cited from NewBeauty, Shape, and Cosmopolitan during 2022.
- 2021
Sofwave lists on the Tel Aviv Stock Exchange[1]
Other
The company completed an initial public offering on the Tel Aviv Stock Exchange, raising $50 million at a reported pre-money valuation of $192 million.
- 2021
Sofwave reports strong 2021 revenue growth[1]
Other
Reported revenue reached $21.8 million in 2021, compared with $4.3 million in 2020 according to the cited growth rate; North American revenue reached $13.5 million.
- 2019
Sofwave raises $8.4 million and begins commercial sales[1]
Other · Product launch
Sofwave raised $8.4 million in a financing led by XT Hi-Tech and began selling its aesthetic ultrasound product late in the year.
Sources2 sources
Cite this profile: Cite the canonical profile. /brand-wiki/sofwave-medical · Editorial policy · How profiles are compiled